The United States Food and Drug Administration (FDA) has granted approval to United States-based Viela Bio for its Breakthrough Therapy Designation of anti-CD19 monoclonal antibody inebilizumab, an investigational monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, life-threatening disease of the central nervous system, it was reported yesterday.
Breakthrough Therapy Designation is designed to accelerate the development and regulatory review of medicines aimed to treat a serious condition that have indicated encouraging early clinical results that may showcase substantial improvement on a clinically significant endpoint over available medicines.
The designation for the product is based on data from the pivotal N-MOmentum study assessing inebilizumab as monotherapy. The study enrolled 231 NMOSD patients for 6.5 months. The primary endpoint was time from initiation of treatment to an NMOSD attack.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial